Stay updated on Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page
- ChecktodayChange DetectedDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.5%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a phase I/II trial of pembrolizumab for CD19+ lymphomas, while adding a new study identifier and a revision number.SummaryDifference46%
- Check29 days agoChange DetectedThe web page has been updated from version v2.14.3 to v2.14.4.SummaryDifference0.3%
- Check37 days agoChange DetectedThe term 'Lymphosarcoma' has been removed and replaced with 'B-cell Lymphoma'.SummaryDifference0.5%
- Check44 days agoChange DetectedDifference0.3%
Stay in the know with updates to Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.